|
KMID : 1146320140020010053
|
|
Journal of Health Technology Assessment
2014 Volume.2 No. 1 p.53 ~ p.63
|
|
|
Comparative Study on Budget Impact Analysis Guideline of Canada, Poland, Belgium and Ireland
|
|
Kim Seong-Ok
Choi Sang-Eun
|
|
|
Abstract
|
|
|
Objectives: This study explored national Budget Impact Analysis (BIA) guideline and analysed commonalities and differences among them.
Methods: We compared the contents of national BIA guidelines developed in Poland (2005), Canada (2007), Belgium (2008/2010), and Ireland (2010/2014).
Results: Budget Impact Analysis (BIA) guidelines were explained and analysed with the items of context of development and participants, scope of analysis and expected usage, perspective, model, time horizon and characteristics of drugs, target population and data sources, cost calculation and resource reallocation, results and uncertainty and sensitivity analysis, inflation, discount rate and etc.
Conclusion: In Korea, pharmaceutical companies should submit BIA as a part of the pharmacoeconomics which is requirement for listing new drug under positive list system, since December 2006. It is important to develop BIA guideline separately from the pharmacoeconomics guideline to advance transparency in decision making process.
|
|
|
KEYWORD
|
|
|
Budget Impact Analysis, Poland, Canada, Belgium, Ireland, ISPOR
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|